MS-DRG 017Medical
Autologous Bone Marrow Transplant without CC/MCC
Pre-MDC·Grouped by diagnosis·FY 2027
MS-DRG 017 is a Medical Medicare Severity Diagnosis Related Group without a significant Complication or Comorbidity. For FY 2027 it carries a relative weight of 4.8891 with a geometric mean length of stay of 9.5 days and an arithmetic mean of 11.7 days. Hospitals use this grouping to determine reimbursement for inpatient stays under Medicare.
Advertisements
FY 2027 payment data
From Table 5 of the FY 2027 IPPS Final Rule (CMS).
- Relative weight:
- 4.8891 (payment multiplier vs. the average case (1.0))
- Geometric mean stay:
- 9.5 days (used for transfer payments)
- Average stay:
- 11.7 days (arithmetic mean)
- Post-acute transfer policy:
- No (not subject to it)
Same condition, other severity levels
CMS splits one condition into separate DRGs by how sick the patient is. With MCC pays more than with CC, which pays more than without CC/MCC.
| DRG | Title | Relative weight | Mean stay |
|---|---|---|---|
| 016 | Autologous Bone Marrow Transplant with CC/MCC | 6.0162 | 15.6 days |
| 017 | Autologous Bone Marrow Transplant without CC/MCC (this page) | 4.8891 | 9.5 days |
Procedure codes (21)
ICD-10-PCS procedures that can group a stay to DRG 017.
- 30233C0Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Peripheral Vein, Percutaneous Approach
- 30233G0Transfusion of Autologous Bone Marrow into Peripheral Vein, Percutaneous Approach
- 30233X0Transfusion of Autologous Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach
- 30233Y0Transfusion of Autologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach
- 30243C0Transfusion of Autologous Hematopoietic Stem/Progenitor Cells, Genetically Modified into Central Vein, Percutaneous Approach
- 30243G0Transfusion of Autologous Bone Marrow into Central Vein, Percutaneous Approach
- 30243X0Transfusion of Autologous Cord Blood Stem Cells into Central Vein, Percutaneous Approach
- 30243Y0Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach
- XW1337ATransfusion of Marnetegragene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
- XW133B8Transfusion of Betibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW133G8Transfusion of Atidarsagene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW133H9Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
- XW133J8Transfusion of Exagamglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8
- XW133SBTransfusion of Mozafancogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
- XW1437ATransfusion of Marnetegragene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 10
- XW143B8Transfusion of Betibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143F8Transfusion of Etuvetidigene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143G8Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143H9Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9
- XW143J8Transfusion of Exagamglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
- XW143SBTransfusion of Mozafancogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 11